Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck Kgaa (OP: MKGAF )

180.98 -4.18 (-2.26%)
Streaming Delayed Price Updated: 12:23 PM EDT, Jun 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 100
Open 178.83
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 185.16
Today's Range 178.83 - 180.98
52wk Range 143.46 - 193.63
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Merck Germany's Two Pivotal Trials Flunk In Multiple Sclerosis
Merck KGaA (OTC: MKGAF) (OTC:  
Via Benzinga
Week In Review: Hengrui Out-Licenses Next-Gen PARP1 To Merck KGaA For $1.7 Billion
Jiangsu Hengrui Pharma out-licensed global rights for its next-gen PARP1 inhibitor to Germany’s Merck KGaA for a $170 million upfront payment and up to $1.5 billion in milestones. Merck will have... 
Via Talk Markets

Performance

YTD
+17.14%
+17.14%
1 Month
+1.53%
+1.53%
3 Month
+3.12%
+3.12%
6 Month
+18.29%
+18.29%
1 Year
+8.52%
+8.52%

More News

Read More
Life Sciences Player Repligen's Strategic European Acquisition - What It Means for Investors
Via Benzinga
Merck Germany Reports 5% Decline In Q2 Sales, Expects More Decline In 2023
Via Benzinga
Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List
Via Benzinga
Abcam Downgrade: Analyst Trims Expectations Amid Activist Investor Engagement and Potential Bid Anticipation
Via Benzinga
Roche's Investigational Drug For Relapsing Multiple Sclerosis Reduces Brain Lesions, Data Shows
Via Benzinga
Analyst Says Nektar Therapeutics' Rezpeg Prioritization Likely to Spark Investor Questions
Via Benzinga
FDA Issues Partial Clinical Hold On Merck Germany's Multiple Sclerosis Study
Via Benzinga
Merck Germany Regains Exclusive Global Rights To Cancer Drug From Pfizer
Via Benzinga
Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval
Via Benzinga
PDS Biotech, Merck Germany Enter Licensing Pact For Investigational Cancer Treatment
Via Benzinga
Mersana Inks Cancer Therapy Development Deal With Merck Germany
Via Benzinga
GlaxoSmithKline, Merck KGaA End $4B Cancer Drug Pact
Via Benzinga
Nektar, Merck Germany, Pfizer Join Forces For Mid-Stage Bladder Cancer Study
Via Benzinga
Merck KGaA Pulls Plug On GSK-Partnered Cancer Drug Trial
Via Benzinga
Sutro Biopharma Receives Undisclosed Milestone Payment Under Bispecific ADC Collaboration with Merck
Via Benzinga
Immutep, Merck Germany Team Up for Eftilagimod/Bintrafusp Combo Trial In Solid Tumors
Via Benzinga
Gene Therapy Player Vera Therapeutics Prices IPO Well Below Range At $11/Share
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
UK's NICE Provisionally Rejects Coverage Of Pfizer-Merck KGaA's Bavencio As First-Line Therapy For Bladder Cancer
Via Benzinga
Palantir Deepens Relationship With Ringier To Help It Transform Into A Digital-First, Global Media Company
Via Benzinga
Novartis Taps Artios In Discovery Pact To Enhance Radioligand Portfolio
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.